SEARCH

SEARCH BY CITATION

References

  • 1
    Castells L, Vargas V, Rodríguez-Frías F, Allende H, Jardi R, Margarit C, et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc 1999; 31:24642465.
  • 2
    Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-Hbc positivity in the donor population. Liver Transpl 2001; 7:5158.
  • 3
    Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infetion after liver transplantation. J Hepatol 1997; 26:517526.
  • 4
    Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:16681674.
  • 5
    Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient liver. Liver Transpl Surg 1997; 3:105111.
    Direct Link:
  • 6
    Safadi R, E'id A, Ilan Y, Ashur Y, Jurim O, Shouval D. Natural course of de novo hepatitis B virus infection in liver transplant recipient. Transpl Proc 1997; 29:26772679.
  • 7
    Manzarbeitia C, Reich D, Ortiz J, Rothstein K, Araya VR, Munoz SJ. Safe use of liver donors with positive hepatitis B core antibody. Liver Transpl 2002; 8:556561.
  • 8
    Fabia R, Levy MF, Crippin J, Tillery W, Netto GJ, Aguanno J, et al. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg 1998; 4:119127.
  • 9
    Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343:142146.
  • 10
    Dodson SF, Issa S, Araya V, Gayowsky T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:15821584.
  • 11
    Uemoto S, Sugiyawa K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65:494499.
  • 12
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 1995; 59:230234.
  • 13
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allograft from anti-HBc-positive donors. Transplantation 1999; 68:10581061.
  • 14
    Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137:572576.
  • 15
    Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16:405409.
  • 16
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.
  • 17
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717.
  • 18
    Brechot C, Kremsdorf D, Paterlini P, Thiers V. Hepatitis B virus DNA in HbsAg-negative patients. Molecular characterization and clinical implications. J Hepatol 1991; 13(suppl 4):549555.
  • 19
    Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant B and C hepatitis infection. Eur J Clin Microbiol Infect Dis 1997; 16:445451.
  • 20
    Crespo J, Fábrega E, Casafont F, Rivero M, de las Heras G, de la Peña J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5:175183.
  • 21
    Radomski JS, Moritz MJ, Armenti VT, Munoz SJ. Hepatitis B transmission from a liver donor who tested negative for hepatitis B surface antigen and positive for hepatitis B core antibody. Liver Transpl Surg 1996; 2:130131.
  • 22
    Wong PY, Marinos G, Peakman M, Tredger JM, Lau JY, Vergani D, et al. FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication. Liver Transpl Surg 1995; 1:362370.
  • 23
    Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81:987991.
  • 24
    Rakela J, Redeker AG, Weliky B. Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 1983; 84:956960.
  • 25
    Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83:16271631.
  • 26
    Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, et al. Reverse seroconversion of hepatitis B after allogenic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 15:616619.
  • 27
    Delmonico FL, Snydman DR. Organ donor screening for infectious diseases: Review of practice and implications for transplantation. Transplantation 1998; 65:603610.
  • 28
    Turner DP, Zuckerman M, Alexander GJ, Waite J, Wreghitt T. Risk of inappropiate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997; 63:775777.
  • 29
    Pasquinelli C, Laure F, Chatenoud L, Beaurin G, Gazengel C, Bismuth H, et al. Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and-negative patients with acute and chronic liver disease. J Hepatol 1986; 3:95103.
  • 30
    Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49:11551158.
  • 31
    Marusawa H, Uemoto S, Hijikata M, Tanaka K, Ueda Y, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31:488495.
  • 32
    Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, et al. Transplantation of livers from HBcAb-positive donors into HBcAb-negative recipients: A strategy and preliminary results. Clin Transplant 2001; 15(suppl 6):5558.
  • 33
    Van Thiel DH, De Maria N, Colantoni A, Friedlander L. Can hepatitis B core antibody positive livers be used safely for transplantation: Hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody-positive. Transplantation 1999; 68:519522.
  • 34
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6:429433.
  • 35
    Lowell JA, Burgerss S, Shenoy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996; 347:480.